Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
The positive top-line results were reported from the phase 3 REFLECTIONS B3281006 study, a randomized, double-blind clinical trial evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-05280586 versus the EU-approved MabThera.
REFLECTIONS B3281006 had an estimated enrollment of 394 adult participants and began in September 2014. It is expected to be completed later in 2018. The primary endpoint, ORR, is defined according to the revised response criteria for malignant lymphoma (time frame, week 26). Secondary outcome measures include time to treatment failure, progression-free survival, complete remission rate, duration of response, overall survival, incidence of anti-drug antibodies, and safety associated with immune response.
“These results reinforce the potential of our proposed rituximab biosimilar in providing a safe and effective treatment option for patients,” said Amrit Ray, MD, global president, Pfizer Essential Health Research and Development. “We are delivering on our commitment to advancing high-quality medicines for the millions of patients with cancer around the world today and in the future,” added Ray.
Pfizer has also investigated the proposed biosimilar for inflammatory indications. An earlier phase 1 clinical trial of PF-05280586 demonstrated pharmacokinetic similarity to US-licensed Rituxan and MabThera in 220 patients with active rheumatoid arthritis (RA) with inadequate response to 1 or more anti—tumor necrosis factor (anti-TNF) therapies. The researchers reported comparable pharmacodynamic responses as well as safety and immunogenicity profiles.
Another clinical trial of PF-05280586 in 214 patients with RA who had an inadequate response to anti-TNF drugs found no clinically meaningful differences in Disease Activity Score in 28 Joints (DAS28) or American College of Rheumatology (ACR) improvement criteria between the proposed biosimilar and the 2 reference drugs.
The complete results of the REFLECTIONS B3281006 trial will be submitted for presentation at a future medical conference or publication in a summary format, according to Pfizer.
Pfizer has 7 distinct biosimilar molecules in mid- to late-stage development, with 3 of these in oncology, as well as several others in early-stage development.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.